Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL1310190

CCCCOC1(c2ccccc2C)CN(C(=O)C(N)Cc2ccc(O)cc2)C1.O=C(O)C(F)(F)F

nearest known ligand 0.48

Full drug profile on Sugi Atlas →

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
MC1R Q01726 8/20 0.48
MC4R P32245 8/20 0.48
HDAC8 Q9BY41 3/20 0.44
OPRD1 P41143 3/20 0.41
HRH2 P25021 1/20 0.39
HRH1 P35367 1/20 0.39
OPRM1 P35372 2/20 0.39
OPRK1 P41145 2/20 0.38
DPP4 P27487 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2154187 0.95 MC1R (0.52) MC1RMC4RHDAC8OPRD1HRH2
Trifluoroacetic Acid SCHEMBL1310217 0.92 MC1R (0.57) MC1RMC4RHRH2HRH1DPP4
Trifluoroacetic Acid SCHEMBL1312510 0.91 MC1R (0.55) MC1RMC4RHRH2HRH1DPP4
SCHEMBL1310191 0.91 MC1R (0.49) MC1RMC4RHDAC8HRH2HRH1
Trifluoroacetic Acid SCHEMBL1311384 0.86 MC1R (0.58) MC1RMC4ROPRD1OPRM1OPRK1
Hydrochloric Acid SCHEMBL1310494 0.86 MC1R (0.60) MC1RMC4RHDAC8HRH2HRH1
Hydrochloric Acid SCHEMBL1310496 0.86 MC1R (0.60) MC1RMC4RHDAC8HRH2HRH1
Trifluoroacetic Acid SCHEMBL14360092 0.85 MC1R (0.48) MC1RMC4RHRH2HRH1DPP4
Trifluoroacetic Acid SCHEMBL1310165 0.84 MC1R (0.49) MC1RMC4RHDAC8DPP4
SCHEMBL16445574 0.83 MC1R (0.61) MC1RMC4R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2342194-B1 OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS GALDERMA RES & DEV (FR) 2018-08-08 EP disclosed
US-9630949-B2 Oxoazetidine derivatives, process for the preparation thereof and use thereof in human medicine and in cosmetics GALDERMA RESEARCH & DEVELOPMENT (FR) 2017-04-25 US disclosed
US-20150045559-A1 OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS GALDERMA RESEARCH & DEVELOPMENT (FR) 2015-02-12 US disclosed
US-8871187-B2 Oxoazetidine derivatives, process for the preparation thereof and use thereon in human medicine and in cosmetics GALDERMA RESEARCH & DEVELOPMENT (FR) 2014-10-28 US disclosed
US-20110274638-A1 OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREON IN HUMAN MEDICINE AND IN COSMETICS GALDERMA RESEARCH & DEVELOPMENT (FR) 2011-11-10 US disclosed
EP-2342194-A1 OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS Galderma Research & Development (FR) 2011-07-13 EP disclosed
WO-2010052253-A1 OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS GALDERMA RESEARCH & DEVELOPMENT (FR) 2010-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110274638-A1 OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREON IN HUMAN MEDICINE AND IN COSMETICS CYP2D6, CYP51A1, CYP2C19 MC1R 326/4885MC4R 1479/4885HDAC8 4312/4885
US-20150045559-A1 OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS CYP51A1, TYR, CYP2C19 MC1R 195/4885MC4R 873/4885HDAC8 4368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.